Kornimate/medical-research-clean huggingface dataset:
study of myms in participants with a diagnosis of multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this is a pilot study looking at the feasibility of a mobile application (app) to collect data from active tasks (questionnaires, 6mapp™, cogapp™, visapp™), clinical magnetic resonance imaging information and conduct genome-wide association studies in subjects with multiple sclerosis. participants will be self-referred to this study from different sources; patient advocacy groups, social media tools, clinicaltrials.gov, and flyers.

this is a pilot study evaluating the feasibility of a mobile application "myms™" to collect active clinical tasks (questionnaires, 6mapp™, cogapp™, visapp™), magnetic resonance imaging information and conduct genome-wide association studies in subjects with multiple sclerosis. participants will be self-referred to this study from different sources; patient advocacy groups, social media tools, clinicaltrials.gov, and flyers. specific aims of this pilot study are: 1. to determine the feasibility and work flow in prospectively collecting surveys, clinical tasks, magnetic resonance imaging (mri) information for up to 200 self-referred adult ms participants, using mobile app myms™. 2. to determine the feasibility of using interface between myms™ and 23andme® dna kits and 23andme password protected mobile app platform (gsr dashboard) in collecting one biological (saliva) sample and distributing the genetic result (using commercially available results only, distributed by 23andme®), for up to 200 self-referred adult ms participants. this aim is for testing the system interface only. 23andme® has their own independent consent form and irb coverage for their commercial product. 3. to estimate the percentage of registered participants that will meet eligibility criteria for ms. 4. to estimate the percentage of participants that a) complete all clinical tasks; b) complete all surveys; c) provide genetic information; and d) provide mri scans.

Eligibility criteria:
inclusion criteria: * males or females participants with access to an iphone 5 and above. * participants willing to provide electronic consent. * age 18 and above. * a diagnosis of ms (polman, 2010), with dissemination in time and space. cis participants will be included if they fulfil 3 of the 4 mri criteria for dissemination in space as per polman et al. 2010. * edss of between 0 and 8.0 exclusion criteria: * under 18 years of age * participants who do not consent to participate. * participants participating in ongoing ms clinical trials with non-approved drugs. * any concurrent illness, disability or clinically significant abnormality (including laboratory tests) that may prevent the subject from safely completing the assessments required by the protocol.

Keywords: ms 23andme mri genome-wide association studies
reducing the acute care burden of childhood asthma on health services in british columbia

Conditions: Upper Respiratory Tract Infection; Asthma

Summary: the purpose of this study is to investigate the benefits of giving filled prescription of a medication to be used upon early onset of symptoms of urti induced asthma. the hope is to reduce the need to present to health care centres for treatment.

in canada, asthma affects more the 12% of children. exacerbation are a common feature of asthma. in children, upper respiratory tract infection (urti's) are responsible for over 80% of asthma exacerbation. experts in asthma care acknowledge this critical problem and have developed guidelines to reduce asthma exacerbation. the criteria for participation in this study to have 2 or more presentations to a health service centre in the past 12 months for urti induced asthma. these patients will be followed and interviewed monthly over a 12 month period to investigate whether the use of oral cortico-steroids upon early onset of urti induced asthma prevents the need for presentation to hospital

Eligibility criteria:
inclusion criteria: * 2 or more presentations to emergency department in a 12 month period exclusion criteria: * less then 2 presentations to emergency department in a 12 month period

Keywords: upper respiratory tract infection asthma urti induced exacerbation of asthma
targeted biopsies in determining response in patients with prostate cancer undergoing high-dose-rate brachytherapy

Conditions: Stage III Prostate Adenocarcinoma

Summary: this pilot clinical trial studies targeted biopsies in determining response in patients with prostate cancer undergoing high-dose-rate brachytherapy (a type of radiation therapy in which radioactive material sealed in needles, seeds, wires, or catheters is placed directly into or near a tumor). studying tumor tissue obtained before and after treatment may help doctors understand changes in a pathway that looks at how deoxyribonucleic acid (dna) is repaired after it is damaged and to see if there are differences in the prostate tissue prior to and after starting androgen deprivation therapy.

primary objectives: i. demonstrate feasibility of obtaining adequate tumor tissue from an intra-prostatic index lesion prior to the start of androgen deprivation therapy (adt) and again at the time of high-dose-rate (hdr) brachytherapy. secondary objectives: i. use immunohistochemistry to stain cells pre-adt and post 2 months of adt for markers of non-homologous end joining and dna double strand breaks using the following markers: ku70, ku80, dna-dependent protein kinase catalytic subunits (pkcs), gamma-histone family, member x (h2ax). outline: patients undergo biopsy at baseline before start of adt and during brachytherapy.

Eligibility criteria:
inclusion criteria: * histologically confirmed primary adenocarcinoma of the prostate * national comprehensive cancer network (nccn) high risk disease (ct3 or gleason score 8-10 or prostate specific antigen \[psa\] \> 20) * not currently on adt * magnetic resonance imaging (mri) or transrectal doppler ultrasound demonstrating at least one target lesion * karnofsky performance status (kps) \>= 70 or eastern cooperative oncology group (ecog) = 2 * understands the trial and procedure and is willing and able to sign the informed consent form exclusion criteria: * patient is unable to receive high dose rate prostate brachytherapy * patient is unable to have a mri or transrectal ultrasound * refusal to sign the informed consent * patients who are participating in a concurrent treatment protocol
effect of nutritional counseling associated with transcranial direct-current stimulation in binge eating reduction

Conditions: Transcranial Direct Current Stimulation; Binge-Eating Disorder; Cognitive Behavioral Therapy

Summary: binge eating disorder is the most prevalent eating disorder, with consequences not only economic but also social. it is related to a set of cognitive alterations related to impulsivity, cognitive function, attention, decision making, emotional control and physiological alterations in the central nervous system (cns) in the processing of rewards, mainly in the frontal cortical regions. psychotherapies are the standard reference treatments, with cognitive behavioral therapy (cbt) being the most indicated nonpharmacological intervention. however, the avoidance rates and the rates of non responders to treatment are significant. in view of this, it is believed that therapeutic approaches aimed at the modulation of the cns, such as transcranial direct-current stimulation (tdcs) may have a beneficial effect on the neurobiology of the processes that govern these disorders, thus adding to the effects of cbt and amplifying the therapeutic response.


Eligibility criteria:
inclusion criteria: * literate * right - handed individuals * body mass index ≥ 25 kg / m2 * meet the criteria of the statistical diagnostic manual of mental disorders 5th edition (dsm - v) for binge eating (4 to 7 episodes of binge eating per week). exclusion criteria: * pregnancy * shift workers * treatment for weight loss in the last 30 days * bariatric surgery * formal contraindication for tdcs
study to assess safety and efficacy of kabiven® in pediatric patients 2 to 16 years of age

Conditions: Malnutrition

Summary: demonstrate the safety and efficacy of kabiven compared to standard parenteral nutrition (pn) administered via central vein in pediatric patients (2 to 16 years of age) requiring pn to meet nutritional needs.


Eligibility criteria:
inclusion criteria: * male or female patients 2 to 16 years of age * patients who require at least 80% of their caloric intake as pn at study start, and in whom an indication for pn is expected for at least 5 days * patients who require a central venous line to receive pn or already have a central venous line in place for other reasons * written informed consent from legal representative(s) exclusion criteria: * known hypersensitivity to egg, soybean proteins, peanut proteins, corn or corn products, or to any of the active substances or excipients * severe hyperlipidemia or severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride concentration \>1,000 g/dl). * inborn errors of amino acid metabolism * cardiopulmonary instability (including pulmonary edema, cardiac insufficiency, myocardial infarction, acidosis and hemodynamic instability requiring significant vasopressor support) * hemophagocytic syndrome. * pn in the last 7 days prior to study enrollment. * need for chronic pn before study start * liver enzymes (either ast, alt, ggpt), or direct bilirubin exceeding 2 x upper limit of normal range * pathologically altered level of any serum electrolyte (sodium, potassium, magnesium, calcium, chloride, phosphate) unless corrected prior to the start of study treatment * pathologically altered blood ph, or oxygen saturation, or carbon dioxide unless corrected prior to the start of study treatment * pregnancy or lactation * participation in another clinical study

Keywords: parenteral nutrition malnutrition pediatrics nutritional needs
comparative study of metformin versus doxycycline in moderate to severe adult acne vulgaris patients.

Conditions: Acne Vulgaris

Summary: the goal of this clinical trial is to compare the effect of doxycycline and metformin in treatment of acne vulgaris patients. the main question is aimed to answer is whether metformin is more effective than doxycycline in treatment of acne vulgaris patient or not. patients will be asked to take doxycycline along with tropical treatment in one group and metformin along with tropical treatment in another group. researcher will compare the clinical improvement in two groups.


Eligibility criteria:
inclusion criteria: newly diagnosed moderate and severe av patients diagnosed by a dermatologist - exclusion criteria: * patients receiving topical retinoids within last two months * pregnancy and lactation * history of corticosteroids intake * suffering from malignancy or any cosmetic induced acne
improving insulin resistance in gynecological cancer patients

Conditions: Insulin Resistance

Summary: this is a research study to see if the addition of cinnamon to a provided food plan would improve insulin resistance in gynecological cancer patients. one study suggests that patients with gynecological cancers are more likely to be insulin resistant and/or have higher levels of fasting insulin. the study will be 24 weeks in length.


Eligibility criteria:
inclusion criteria: * previously diagnosed with gynecological cancer and has completed all surgical intervention, chemotherapy, and/or radiation at least 3 months prior to enrollment but not greater than 24 months * post-menopausal * bmi \> 25 but \< 40 exclusion criteria: * no previous diagnosis of diabetes * no other cancer diagnosis (excluding skin) * no chronic use of medication(s) interfering with glucose metabolism
mulligan snag technique in individuals with lumbar intervertebral disc protrusion

Conditions: Intervertebral Disc Protrusion

Summary: this study aimed to examine the effects of the mulligan snag mobilization technique, applied in addition to conventional physiotherapy on the structure of the intervertebral disc and physical functioning in patients diagnosed with low back pain due to lumbar intervertebral disc protrusion. 38 volunteer patients will participate in the study. the participants will be randomized as an interventional and control gropus.

participants will be treated 3 days a week for 4 weeks. the session duration will be 40-45 minutes. visual analog scale-vas, oswestry disability index, magnetic imaging-mri assessment, functıonal independence scale-fim, tampa kinesiophobia scale, one leg stand test, sit-stand test, 10-meter walking test, cadence , nottingham health profile will be used to assses the participants in the two groups. all participants will be evaluated in the 5th week of the study. the program includes physical therapy session (hot packed, trans cuteneal electric stimulation, therapeutic ultrasound, and therapautic exercises) and the mulligan snag mobilization technique.

Eligibility criteria:
inclusion criteria: 1. being between the ages of 20-60 2. those diagnosed with lumbar intervertebral disc heniation (protrusion on l1-l2, l2-l3, l3-l4, l4-l5, l5-s1) at a single level 3. those who voluntarily agreed to participate in the study exclusion criteria: * individuals diagnosed with lumbar bulging, extruded, sequestered discs * individuals who have undergone lumbar region spinal surgery * individuals with spinal deformity (scoliosis, spondylolisthesis, ankylosing spondylitis) * individuals with lumbar stenosis * pregnant women * individuals receiving treatment for malignancy (primary or metastatic tumoral conditions in the lumbar region) * individuals diagnosed with advanced osteoporosis * individuals diagnosed with discitis

Keywords: lumbar disc herniation mulligan snag technique low back pain mri physical functioning quality of life
photobiomodulation for cancer-related cognitive impairment

Conditions: Cancer-related Cognitive Impairment

Summary: this is a single site, pilot randomized, double blinded control trial designed to assess changes in cognitive symptoms in cancer survivors with cancer-related cognitive impairment. patients will be randomized into one of two arms: intervention or control. * arm a: intervention group: use of the thor led photobiomodulation helmet 3x per week for 6 weeks. helmet will be in 'therapeutic setting', 35mw/cm2 = 42j/cm2 * arm b: control group: use of the thor led photobiomodulation helmet 3x per week for 6 weeks. helmet will be in 'placebo setting', 0mw/cm2 = 0j/cm2 this study has been designed to assess the hypothesis that photobiomodulation can have a positive impact on cognitive symptoms in cancer survivors with cancer-related cognitive impairment. 30 participants will be recruited for this study, 15 per group. self-report questionnaires assessing cognitive concerns, cognitive abilities, quality of life, depression, and anxiety will be administered at three timepoints through the study baseline, end of study visit and 1 month follow up


Eligibility criteria:
inclusion criteria: * adults ≥ 18 years * previous diagnosis of stage i-iii non-central nervous system solid tumor malignancy, hodgkin, or non-hodgkin lymphoma * completed cancer treatment (chemotherapy and/or radiation) more than 6 months ago but less than 5 years ago (current concurrent endocrine therapy, anti-her-2 therapy allowed, or other stable maintenance therapies (such as rituximab) will be allowed. * self-reported cognitive complaints (score ≤ 54 on the functional assessment of cancer therapy-cognition, version 3, perceived cognitive impairment subscale) * written informed consent obtained from subject and ability for subject to comply with the requirements of the study. * ability to read, write and understand either english or spanish. exclusion criteria: * current pregnancy or nursing status * current use of photobiomodulation (pbm) (for any reason) * a lifetime history of any brain tumor or central nervous system metastasis * previous use of intrathecal chemotherapy, chimeric antigen receptor treatment (car-t), or stem cell/marrow transplant * known history of other neurological conditions involving impaired cognitive function (such as alzheimer's disease and related dementias, parkinson's disease, or multiple sclerosis).

Keywords: cancer survivor
vitamin b12 and folate administration on homocysteine concentrations after nitrous oxide anesthesia

Conditions: Cardiovascular Abnormalities

Summary: the goal of this study is to find out if giving intravenous b-vitamins before general anesthesia with nitrous oxide prevents the increase in homocysteine, a metabolite that has been linked to cardiovascular complications.

patients will be randomized into the following arms: * arm a: patients will receive n2o (60% n2o/40% o2) in an open-label fashion during surgery and vitamin supplementation (vitamin b12, 1 mg, and folate, 5 mg) before surgery. * arm b: patients will receive n2o 60% n2o/40% o2) in an open-label fashion during surgery and placebo before and after surgery. * arm c: patients will not receive n2o, vitamin supplementation, or placebo during/before surgery. patients in this arm will not be randomized. patients will have blood drawn (total of 1-2 teaspoons over 3 days). we will take these samples before their surgery, when their surgery is completed, and in the morning of post-operative day 1. we will be checking their troponin i and troponin t, homocysteine, vitamin b12, and folate levels. we will also perform a 12-lead ekg. before and after surgery for patients in arm a or b, will receive either vitamin b12 (1 mg) and folic acid (5 mg) (or placebo) added to their iv infusion. we also plan to use a non-invasive test known as a nerve conduction study to measure the function of their nerve system. briefly, 2 small electrodes are attached to their skin over a nerve and, like an ekg, faint electrical pulses are generated and recorded. a typical nerve conduction measurement lasts about 10 minutes. after the patients surgery we will do genetic testing of mthfr genotype. all study samples have been collected. of note: there were no secondary outcomes.

Eligibility criteria:
inclusion criteria: * adult patients scheduled for elective surgery with expected duration \> 2 hours * healthy patients undergoing moderate surgery where the use of n2o is unproblematic exclusion criteria: * contraindication against n2o (pneumothorax, mechanical bowel obstruction, middle ear occlusion, laparoscopic surgery, raised intracranial pressure) * patients requiring supplemental oxygen * urgent or emergent surgery * patients with vitamin b12 or folate deficiency or megaloblastic anemia * patients with seizure disorder (epilepsy) * allergy or hypersensitivity against iv cobalamin or folate * patients with leber's disease (hereditary optic nerve atrophy) * patients taking supplemental vitamin b12 or folate

Keywords: nitrous oxide cobalamin homocysteine vitamin b12 folate no specific diseases targeted
a new optical sweat test method based on a citric acid-derived multi-halide sensor

Conditions: Cystic Fibrosis

Summary: cystic fibrosis (cf) is a hereditary multi-system disease affecting approximately 30,000n children and adults in the usa. the diagnosis of cf requires biochemical confirmation (either abnormal sweat chloride measurement and/or identification of two cf disease causing mutations) plus clinical symptomatology. measurements of sweat chloride remain cumbersome and although most common methodology to confirm cf diagnosis with limitations especially in young children less than 6 months of age and in areas that lack ability for the complex testing. the study objectives of this current research proposal include: a) to expand upon previously obtained pilot study data "evaluation of a fluorescent-based chloride sensor as an optical sweat test to diagnose cystic fibrosis" b) to add the exploratory measurement of sweat bromide as a first in human assessment observation, c) to evaluate the development of smartphone based point-of-care technology for chloride and bromide sensor measurements, d) to further expand the class of citrate-based sensors with improved fluorescence and sensing properties for the design of new fluorescence-based analytical and diagnostic solutions based on the automated multi-halide detection system, and e) to develop point-of-care systems that can successfully integrate into clinical settings to improve current practices and facilitate early detection of disease.


Eligibility criteria:
inclusion criteria: * adults 18 years of age or older capable of providing written informed consent and * patients with an established diagnosis of cystic fibrosis (cf) or healthy volunteers exclusion criteria: * participants under medications or with disorders known to cause a positive error in the sweat test will be excluded in the study. common causes of positive error in sweat test are mineralocorticoid hormone therapy, adrenal insufficiency, glycogen storage diseases, hypothyroidism, hypoparathyroidism, nephrogenic diabetes insipidus, g6pd deficiency or ectodermal dysplasia or * any other skin or soft tissue disorders that could affect obtaining the necessary volumes of sweat.
effect of climatic factors on the seasonal fluctuation of pulmonary embolism

Conditions: Pulmonary Embolism

Summary: to estimate the risks of daily hospital admissions for pulmonary embolism associated with short term exposure to climatic factors (temperature, precipitation, air pressure, sunshine duration, relative humidity, wind speed, and ambient fine particulate matter \[aerodynamic diameter ≤2.5 μm; pm2.5\]) in china.

hospital admissions for pulmonary embolism were identified based on the primary diagnosis. the central adjudication committee at peking union medical college hospital (beijing, china) reviewed all medical and death records and determined the final diagnosis. two adjudication committee members verified events independently, and discrepancies were resolved by discussion involving additional committee members.for each admission, we extracted data on the date of admission, sex, age, and location of the patient from hospital information system. all the data of daily meteorological variables for the same period, including temperature variables (°c) (the min, max and mean temperature), relative humidity (%), air pressure (hpa), precipitation (mm), wind speed (m/s) and sunshine duration (h), were collected from the china meteorological data sharing service system (http://www.escience.gov.cn/metdata/page/index.html). the data on pm2.5 levels in each city was collected from the national air pollution monitoring system. an overdispersed generalised additive model was used to estimate associations between climatic factors and pulmonary embolism admissions. a distributed lag non-linear model (dlnm) was employed to examine their lagged effects.

Eligibility criteria:
inclusion criteria: * males and females. * with a primary diagnosis of pulmonary embolism based on clinical symptoms, with or without radiologic features. exclusion criteria: * lack of important data.

Keywords: pulmonary embolism climate